333 related articles for article (PubMed ID: 36633661)
1. Complete remissions following immunotherapy or immuno-oncology combinations in cancer patients: the MOUSEION-03 meta-analysis.
Santoni M; Rizzo A; Kucharz J; Mollica V; Rosellini M; Marchetti A; Tassinari E; Monteiro FSM; Soares A; Molina-Cerrillo J; Grande E; Battelli N; Massari F
Cancer Immunol Immunother; 2023 Jun; 72(6):1365-1379. PubMed ID: 36633661
[TBL] [Abstract][Full Text] [Related]
2. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
[TBL] [Abstract][Full Text] [Related]
3. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2021 Apr; 4(4):CD013257. PubMed ID: 33930176
[TBL] [Abstract][Full Text] [Related]
4. Hypertransaminasemia in cancer patients receiving immunotherapy and immune-based combinations: the MOUSEION-05 study.
Rizzo A; Mollica V; Tateo V; Tassinari E; Marchetti A; Rosellini M; De Luca R; Santoni M; Massari F
Cancer Immunol Immunother; 2023 Jun; 72(6):1381-1394. PubMed ID: 36695827
[TBL] [Abstract][Full Text] [Related]
5. Peripheral neuropathy and headache in cancer patients treated with immunotherapy and immuno-oncology combinations: the MOUSEION-02 study.
Rizzo A; Santoni M; Mollica V; Logullo F; Rosellini M; Marchetti A; Faloppi L; Battelli N; Massari F
Expert Opin Drug Metab Toxicol; 2021 Dec; 17(12):1455-1466. PubMed ID: 35029519
[TBL] [Abstract][Full Text] [Related]
6. Systemic treatments for metastatic cutaneous melanoma.
Pasquali S; Hadjinicolaou AV; Chiarion Sileni V; Rossi CR; Mocellin S
Cochrane Database Syst Rev; 2018 Feb; 2(2):CD011123. PubMed ID: 29405038
[TBL] [Abstract][Full Text] [Related]
7. Association of Anticancer Immune Checkpoint Inhibitors With Patient-Reported Outcomes Assessed in Randomized Clinical Trials: A Systematic Review and Meta-analysis.
Pala L; Sala I; Oriecuia C; De Pas T; Queirolo P; Specchia C; Cocorocchio E; Ferrucci P; Patanè D; Saponara M; Pennacchioli E; Coppola S; Viale G; Giaccone G; Gelber RD; Bagnardi V; Conforti F
JAMA Netw Open; 2022 Aug; 5(8):e2226252. PubMed ID: 35972744
[TBL] [Abstract][Full Text] [Related]
8. Immune checkpoint inhibitors, alone or in combination with chemotherapy, as first-line treatment for advanced non-small cell lung cancer. A systematic review and network meta-analysis.
Dafni U; Tsourti Z; Vervita K; Peters S
Lung Cancer; 2019 Aug; 134():127-140. PubMed ID: 31319971
[TBL] [Abstract][Full Text] [Related]
9. The impact of ECOG performance status on efficacy of immunotherapy and immune-based combinations in cancer patients: the MOUSEION-06 study.
Mollica V; Rizzo A; Marchetti A; Tateo V; Tassinari E; Rosellini M; Massafra R; Santoni M; Massari F
Clin Exp Med; 2023 Dec; 23(8):5039-5049. PubMed ID: 37535194
[TBL] [Abstract][Full Text] [Related]
10. Comparative efficacy and safety of first-line treatments for advanced non-small cell lung cancer with immune checkpoint inhibitors: A systematic review and meta-analysis.
Chen R; Hou X; Yang L; Zhao D
Thorac Cancer; 2019 Apr; 10(4):607-623. PubMed ID: 30734504
[TBL] [Abstract][Full Text] [Related]
11. Immunotherapy for advanced renal cell cancer.
Coppin C; Porzsolt F; Awa A; Kumpf J; Coldman A; Wilt T
Cochrane Database Syst Rev; 2005 Jan; (1):CD001425. PubMed ID: 15674877
[TBL] [Abstract][Full Text] [Related]
12. Complete response to immune checkpoint inhibitors-based therapy in advanced renal cell carcinoma patients. A meta-analysis of randomized clinical trials.
Iacovelli R; Ciccarese C; Schutz FA; Tortora G; de Velasco G
Urol Oncol; 2020 Oct; 38(10):798.e17-798.e24. PubMed ID: 32773231
[TBL] [Abstract][Full Text] [Related]
13. First-line Immunotherapy-based Combinations for Metastatic Renal Cell Carcinoma: A Systematic Review and Network Meta-analysis.
Quhal F; Mori K; Bruchbacher A; Resch I; Mostafaei H; Pradere B; Schuettfort VM; Laukhtina E; Egawa S; Fajkovic H; Remzi M; Shariat SF; Schmidinger M
Eur Urol Oncol; 2021 Oct; 4(5):755-765. PubMed ID: 33757737
[TBL] [Abstract][Full Text] [Related]
14. The impact of gender on The efficacy of immune checkpoint inhibitors in cancer patients: The MOUSEION-01 study.
Santoni M; Rizzo A; Mollica V; Matrana MR; Rosellini M; Faloppi L; Marchetti A; Battelli N; Massari F
Crit Rev Oncol Hematol; 2022 Feb; 170():103596. PubMed ID: 35031442
[TBL] [Abstract][Full Text] [Related]
15. The Long-Term and Short-Term Efficacy of Immunotherapy in Non-Small Cell Lung Cancer Patients With Brain Metastases: A Systematic Review and Meta-Analysis.
Chu X; Niu L; Xiao G; Peng H; Deng F; Liu Z; Wu H; Yang L; Tan Z; Li Z; Zhou R
Front Immunol; 2022; 13():875488. PubMed ID: 35693805
[TBL] [Abstract][Full Text] [Related]
16. Impact of Clinicopathological Features on Survival in Patients Treated with First-line Immune Checkpoint Inhibitors Plus Tyrosine Kinase Inhibitors for Renal Cell Carcinoma: A Meta-analysis of Randomized Clinical Trials.
Rizzo A; Mollica V; Santoni M; Ricci AD; Rosellini M; Marchetti A; Montironi R; Ardizzoni A; Massari F
Eur Urol Focus; 2022 Mar; 8(2):514-521. PubMed ID: 33714725
[TBL] [Abstract][Full Text] [Related]
17. Immune-based combinations for the treatment of metastatic renal cell carcinoma: a meta-analysis of randomised clinical trials.
Massari F; Rizzo A; Mollica V; Rosellini M; Marchetti A; Ardizzoni A; Santoni M
Eur J Cancer; 2021 Sep; 154():120-127. PubMed ID: 34265504
[TBL] [Abstract][Full Text] [Related]
18. Patients with sarcomatoid renal cell carcinoma - re-defining the first-line of treatment: A meta-analysis of randomised clinical trials with immune checkpoint inhibitors.
Iacovelli R; Ciccarese C; Bria E; Bracarda S; Porta C; Procopio G; Tortora G
Eur J Cancer; 2020 Sep; 136():195-203. PubMed ID: 32712550
[TBL] [Abstract][Full Text] [Related]
19. Anti-epidermal-growth-factor-receptor agents and complete responses in the treatment of advanced non-small-cell lung cancer: a meta-analysis of 17 phase III randomized controlled trials.
Qi WX; Fu S; Zhang Q; Guo XM
Curr Med Res Opin; 2015 Jan; 31(1):25-33. PubMed ID: 25329826
[TBL] [Abstract][Full Text] [Related]
20. Immunotherapy (excluding checkpoint inhibitors) for stage I to III non-small cell lung cancer treated with surgery or radiotherapy with curative intent.
Zhu J; Li R; Tiselius E; Roudi R; Teghararian O; Suo C; Song H
Cochrane Database Syst Rev; 2017 Dec; 12(12):CD011300. PubMed ID: 29247502
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
